PROSTATE CANCER
Prostate cancer is one of the most common illnesses in older
men. It is detected by routine examination of the prostate in 20% of 60
year-old men, and in 60% of 80 year-old men, even when the patient has
no symptoms. The minor symptoms of prostate cancer can be deceptive; it
is a very serious disease. A small, early-phase carcinoma lying in the
urethra can get into the bloodstream via the sperm or urine. Lying within
the prostate, these small carcinomas cause no discomfort, and generally
cannot be found this early except through a PSA test. It is entirely possible
for the cancer tissue to go undetected for a long time. The typical prostate
complaints of slight or reduced urination, occasional burning during urination
or difficult urination, or post-urination drip are some non-specific symptoms
that can appear in normal cases as well as in older men experiencing prostate
enlargement.
One of the best options for detecting prostate cancer is palpation of the prostate by a physician to discover a lump or hardening in the normally elastic prostate tissue. Another very informative early detection test, which can also be a part of treatment, is the test for PSA (Prostate Specific Antigen) in the blood. PSA is a substance that the prostate cancer cells give off, and which can be measured in the blood. In the normal prostate enlargement that is associated with age and hormonal change, test readings are negative or slightly raised. With a new test, the PSA can be divided into total and “free” PSA. According to the proportion of “free” PSA relative to the total PSA, normal or abnormal prostate enlargement can be indicated. Another even newer test that is used in PBM for early detection of tumor growth is the TPS (Tissue Polypeptide Specific Antigen) test, which indicates early metastasis and tumor growth.
As metastasis appears in the cells, it frequently spreads to the bones and lymphatic system. Its presence in the bone can be detected by measuring alkaline phosphatase in the blood. The more active the bone displacement by cancer cells, the higher the alkaline phosphatase. Somewhat more specific is the Acid Prostate-Phosphatase test. Two other somewhat more costly tests for metastasis are x-ray and skeletocintigraphy. In this later test, a small amount of radioactive material is injected and accumulates in the prostate-metastasized tissue in the bone, and is detected via fluororadiography. Other early indicator tests are the Thermoregulation Diagnostic, Darkfield microscopy of the blood, and BioTerrain Assessment. These give indications as to how the carcinoma tendency should be treated and which biological therapies should be assembled.
From the PBM perspective, development of tumors is reflective of a tendency toward degenerative disease. This tendency toward cancer is often precipitated by the presence of heavy metals in the body, poisons from root canals, trace element and vitamin deficiencies, and severe emotional stress, among other factors. The therapeutic must address this underlying tendency toward cancer as well as the tumorous condition itself. Treatment includes vitamin therapy, enzyme therapy, strengthening the immune system, blood cleansing with isopathic therapies, and especially dental assessment with heavy metal removals.
In certain prostate carcinomas, dose hormone therapy may be injected in and around the tumor; this has been known to bring down the PSA value within a month. This individual hormone dosage is combined with antibody-binding Haptenen (a specific polysaccharide molecule and cytokines (substances that stimulate tumor-killing lymphocytes). This treatment in combination with local hyperthermia is particularly effective in dropping PSA; the drop indicates a reduction in tumor size and infiltration.
The overall prostate treatment takes at least a year to reach full effectiveness, but the results are outstanding: 80% of our cases achieve a halt or a retreat in tumor growth. We do not recommend chemotherapy for prostate carcinoma, as the success rate is very low, We seldom recommend surgery early on for the same reason: in most cases, it offers no more success than other treatments.
Three further important components of the Paracelsus Tumor Healthcare Program are:
• Local Hyperthermia (Indiba): A heat therapy using current technology with deep heating of the local tissue area. A very high local heat is produced, particularly in firm tissue. Tumor cells do not support this level of heat, and die back while healthy tissue is strengthened in the heat. Metabolism is also increased by this treatment. Hyperthermia is applied locally and is totally painless. Application is ideally two to three times per week; for some individuals, this treatment works well with fewer applications. This therapy is a specialty of the Paracelsus Clinic and is practiced nowhere else in Switzerland. Within about twenty treatments, the tumor tissue can be regenerated bringing about a scarring over and connective tissue change in the tumor.
• Mistletoe Therapy: Mistletoe therapy, which is an injection of a mistletoe preparation, is a well-researched tumor treatment, and a pillar of the Paracelsus tumor treatment. In prostate cancer, the pre parations are injected subcutaneously in the groin or abdomen by the patient in increasing dosages twice weekly. The patient is taught the simple injection technique.
• In addition to these specifically named cancer treatments, we follow an ongoing protocol of rebuilding the inner environment, and treatment and removal of all factors that lead to the malignant degeneration of the tissue.
We call these therapies the Paracelsus Tumor Healthcare Program. Further information on the Tumor Healthcare Program can be found here.
One of the best options for detecting prostate cancer is palpation of the prostate by a physician to discover a lump or hardening in the normally elastic prostate tissue. Another very informative early detection test, which can also be a part of treatment, is the test for PSA (Prostate Specific Antigen) in the blood. PSA is a substance that the prostate cancer cells give off, and which can be measured in the blood. In the normal prostate enlargement that is associated with age and hormonal change, test readings are negative or slightly raised. With a new test, the PSA can be divided into total and “free” PSA. According to the proportion of “free” PSA relative to the total PSA, normal or abnormal prostate enlargement can be indicated. Another even newer test that is used in PBM for early detection of tumor growth is the TPS (Tissue Polypeptide Specific Antigen) test, which indicates early metastasis and tumor growth.
As metastasis appears in the cells, it frequently spreads to the bones and lymphatic system. Its presence in the bone can be detected by measuring alkaline phosphatase in the blood. The more active the bone displacement by cancer cells, the higher the alkaline phosphatase. Somewhat more specific is the Acid Prostate-Phosphatase test. Two other somewhat more costly tests for metastasis are x-ray and skeletocintigraphy. In this later test, a small amount of radioactive material is injected and accumulates in the prostate-metastasized tissue in the bone, and is detected via fluororadiography. Other early indicator tests are the Thermoregulation Diagnostic, Darkfield microscopy of the blood, and BioTerrain Assessment. These give indications as to how the carcinoma tendency should be treated and which biological therapies should be assembled.
From the PBM perspective, development of tumors is reflective of a tendency toward degenerative disease. This tendency toward cancer is often precipitated by the presence of heavy metals in the body, poisons from root canals, trace element and vitamin deficiencies, and severe emotional stress, among other factors. The therapeutic must address this underlying tendency toward cancer as well as the tumorous condition itself. Treatment includes vitamin therapy, enzyme therapy, strengthening the immune system, blood cleansing with isopathic therapies, and especially dental assessment with heavy metal removals.
In certain prostate carcinomas, dose hormone therapy may be injected in and around the tumor; this has been known to bring down the PSA value within a month. This individual hormone dosage is combined with antibody-binding Haptenen (a specific polysaccharide molecule and cytokines (substances that stimulate tumor-killing lymphocytes). This treatment in combination with local hyperthermia is particularly effective in dropping PSA; the drop indicates a reduction in tumor size and infiltration.
The overall prostate treatment takes at least a year to reach full effectiveness, but the results are outstanding: 80% of our cases achieve a halt or a retreat in tumor growth. We do not recommend chemotherapy for prostate carcinoma, as the success rate is very low, We seldom recommend surgery early on for the same reason: in most cases, it offers no more success than other treatments.
Three further important components of the Paracelsus Tumor Healthcare Program are:
• Local Hyperthermia (Indiba): A heat therapy using current technology with deep heating of the local tissue area. A very high local heat is produced, particularly in firm tissue. Tumor cells do not support this level of heat, and die back while healthy tissue is strengthened in the heat. Metabolism is also increased by this treatment. Hyperthermia is applied locally and is totally painless. Application is ideally two to three times per week; for some individuals, this treatment works well with fewer applications. This therapy is a specialty of the Paracelsus Clinic and is practiced nowhere else in Switzerland. Within about twenty treatments, the tumor tissue can be regenerated bringing about a scarring over and connective tissue change in the tumor.
• Mistletoe Therapy: Mistletoe therapy, which is an injection of a mistletoe preparation, is a well-researched tumor treatment, and a pillar of the Paracelsus tumor treatment. In prostate cancer, the pre parations are injected subcutaneously in the groin or abdomen by the patient in increasing dosages twice weekly. The patient is taught the simple injection technique.
• In addition to these specifically named cancer treatments, we follow an ongoing protocol of rebuilding the inner environment, and treatment and removal of all factors that lead to the malignant degeneration of the tissue.
We call these therapies the Paracelsus Tumor Healthcare Program. Further information on the Tumor Healthcare Program can be found here.